About Biocon Our Business Research & Development Biocon's Technology Investors Media Careers CSR
  Press Releases
  Download Center
  Video Gallery
  Photo Gallery
  Media Contacts

Company Statement

Biocon's Insulin Manufacturing Facility in Malaysia Completes U.S. FDA (PAI) Inspection

Bengaluru, Karnataka, India, Feb 22, 2020

This is to inform you that the U.S. Food and Drug Administration (FDA) conducted a pre-approval inspection (PAI) of our subsidiary, Biocon Sdn. Bhd’s Insulins manufacturing facility based in Malaysia, for Insulin Glargine, between Feb 10 and Feb 21, 2020.

At the conclusion of the inspection, the agency issued a Form 483 with 3 observations which we believe are procedural in nature.

We will respond to the FDA with an appropriate Corrective and Preventive Action Plan (CAPA) and are confident of addressing these observations expeditiously. The FDA has set a Target action date for our Insulin Glargine application in June 2020. We believe the outcome of this inspection does not in any way impact the commercialization plans of insulin glargine in the US. Biocon Biologics is committed to global standards of Quality and Compliance.”

- Company Spokesperson

<< Back


Download the
Company Statement


Recommended sites Biocon on  
About Us

Investor Relations
Media Relations
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Research Services
Active Discovery Program

Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
  Report adverse event/side effects and product complaints    
  * Disclaimer            © 2018, Biocon. All Rights Reserved